All In Biotech

Free tool

FAERS Monitor: Epiduo Forte

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207917 or its brand name (Epiduo Forte, Adapalene, Benzoyl Peroxide). Reports on generic versions are filed under their own applications.

Reports

54

Serious

22

41% of reports

Hospitalization

9

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective9
  • rash6
  • acne4
  • erythema4
  • application site pain3
  • application site pruritus3
  • burning sensation3
  • pruritus3
  • application site erythema2
  • application site irritation2
  • dermatitis atopic2
  • drug hypersensitivity2
  • drug interaction2
  • dry skin2
  • fluid retention2

Reports by year received

View as table
YearReports
20132
20142
20151
20161
20171
20181
20197
20207
20213
20223
20236
202410
20257
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site irritation262.616.168
application site painSignal353.117.7106
application site pruritusSignal351.517.1102
application site erythema229.77.631
acneSignal420.58.056
burning sensationSignal316.75.530
fluid retention215.33.914
dermatitis atopic214.83.814
erythemaSignal47.63.017
dry skin25.81.54
rashSignal65.42.518
drug interaction24.91.33
drug hypersensitivity24.01.02
pruritus33.01.02
drug ineffectiveSignal92.71.58

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.